A Phase 1, Open Label, Randomized, Single Dose, Dose Escalation Study To Assess The Subcutaneous Pharmacokinetics And Pharmacodynamics Of Bococizumab (PF-04950615) Alone and in Co-Mixture With Recombinant Human Hyaluronidase (rHuPH20, PF-06744547) in Healthy And Hypercholesterolemic Adult Subjects

Trial Profile

A Phase 1, Open Label, Randomized, Single Dose, Dose Escalation Study To Assess The Subcutaneous Pharmacokinetics And Pharmacodynamics Of Bococizumab (PF-04950615) Alone and in Co-Mixture With Recombinant Human Hyaluronidase (rHuPH20, PF-06744547) in Healthy And Hypercholesterolemic Adult Subjects

Discontinued
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2016

At a glance

  • Drugs Bococizumab (Primary) ; Hyaluronidase (Primary)
  • Indications Hypercholesterolaemia
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 01 Aug 2016 Status changed from active, no longer recruiting to discontinued.
    • 20 Jul 2016 Status changed from recruiting to active, no longer recruiting.
    • 23 Feb 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top